Scius Communications is focused on providing strategic communications to life science companies at all stages of development to support the achievement of your corporate objectives, whether they be partnering or financing. We will help you deliver your story to your target audiences through multiple, impactful communications channels that build value for your company. 



Our team has a unique insight that has been gained from holding leadership positions in pharmaceutical business development and commercial strategy, investment firms and communications consultancies. This enables us to brings a well informed perspective to our communications strategy and provide valuable and trusted counsel that fosters long-term client relationships.

Katja Stout, MBiochem (Oxon), MBA
Managing Director

Katja is a communications strategist and entrepreneur with over twenty years of international experience in the life sciences and pharmaceutical industry. A serial entrepreneur, she has founded two communications consultancies.

As Managing Director and Founder of Scius Communications, Katja supported Immunocore’s $320 million financing, Europe’s largest ever private round in life sciences. Katja has also supported BC Platforms in its communications strategy and media outreach for over three years. As Co-Founder and a Board Director of Northbank communications, a leading global specialist life sciences communications firms, Katja supported the company’s growth to over 35 staff and 100 clients prior to its successful sale to College Hill (now Instinctif).

Subsequently Katja spent four years at AstraZeneca firstly as Director of Partnering Communications in the business development team and supported AZ’s notable rise in the industry league tables from number 12 to number 3 as the ‘partner of choice’. She later became Vice President of Corporate Affairs, Global Product and Portfolio Strategy (GPPS) and was a member of the GPPS leadership team. In this role she was responsible for leading the communications for all of AstraZeneca’s global product brands and launching the new GPPS function internally.

Prior to founding Northbank, Katja held in-house roles at leading investment firms including SV Life Sciences, International BioTechnology Trust and Merlin Biosciences. She also worked at life sciences investor relations firm, Russell-Welsh (now GCI Healthcare), based in San Francisco, California. Earlier in her career, Katja was Head of communications and IR at Genset SA (now part of Merck Serono), a pioneer in personalised healthcare, listed on Nasdaq and the Nouveau Marche and based in Paris.

Katja has a Masters degree in Biochemistry from Oxford University and an MBA from Imperial College London.

Daniel Gooch

Daniel Gooch brings over twenty years of communications, policy, & public affairs experience, specialised in life sciences, with a focus on rare diseases, gene therapy and genetic testing. Daniel has utilised this extensive experience to support a wide range of US, European and Australian life sciences clients including start-ups, private and public biotech companies, pharmaceutical companies, and member associations.

Daniel helps companies craft their messages, and brand communications, for a wide range of audiences, building corporate value and enhancing reputation. Notable client experience includes Ablynx, Agendia, AmpliPhi, Astex Pharmaceuticals, Bluebird Therapeutics, Dimerix, F-Star, Forbion Capital Partners, Hookipa, Molecular Partners, Novartis, Polyganics, Prosensa, Sarepta Therapeutics, & Xellia Pharmaceuticals.

In 2010, he moved into communications and lobbying work following over a decade’s career in the UK civil service, where he covered science policy including gene therapy, genetic testing and industrial strategies.

Daniel originally trained as a fermentation development scientist in the legacy companies of Roche in Germany, and GSK in the UK, producing novel biologics for treating cancer. He has an Masters degree in Biotechnology, a First in Applied Biology, and CAM qualifications in PR, advertising and marketing.

Daniel also supports local Government and charity work, helping London’s City Hall make London the best place to do business, and helping the voices of people with rare conditions be heard in the UK Parliament, to secure better access to medicines.

Vivian Chen
Investor Relations Consultant
New York

Vivian Chen brings with her over nineteen years of healthcare investment banking, capital markets and investor relations experience.  Ms. Chen utilizes her extensive corporate finance, capital raising and marketing skills to build highly impactful strategic communications programs for clients across various global verticals centered around emerging technologies and healthcare.

Ms. Chen offers unique insight into what the investment community values and translates this information into succinct, actionable and tangible communications to build corporate value amidst regulatory, trade and investment communities.  Ms. Chen works with management to execute and accomplish their corporate objectives by identifying strategic partners, assisting in capital formation and garnering interest from analysts globally.  Vivian employs a 360 degree approach to marketing and communications to maximize value for her clients to include highly targeted global analyst days, KOL roundtable discussions, special corporate events, trade shows, media engagements and global roadshows in key financial centers. Vivian has executed over 1000 non-deal roadshow days, secured over 40 research initiation reports, 100 conference invitations, 15 NASDAQ / NYSE IPOs & listing ceremonies, dual-listings and nearly $750 million in funding for her clients.

Vivian transitioned into investor relations after having worked nearly eight years at Citigroup’s Global Consumer and Health Care investment banking group serving dual marketing and corporate finance roles at the Vice President level.  She successfully raised over $16 billion in gross proceeds for companies across the equity, fixed income and mergers and acquisitions platforms.

Vivian holds a Master in Business Administration from Washington University with an emphasis in finance and accounting and a B.S. degree from the University of Southern California with an emphasis in management and marketing. She is based in New York City.

Cathy Loos
Media Relations Consultant
New York

Cathy Loos has over 20 years of experience in marketing communications and media relations program strategy development and execution. She has a core expertise in financial media relations, with a focus on sectors including healthcare and biotechnology and metals, mining and resources.

Cathy was previously a senior media relations specialist at CCG Investor Relations, where she managed media relations programs and marketing support for clients, including, NeuroSigma, NeoStem, and Colombia Energy Resources, among others. Cathy’s previous experience also includes roles as a Vice President at media relations firms, including WT Blase & Associates, and G.S. Schwartz & Co./Middleberg Communications. Prior to that, Cathy was a Vice President at MBNA America Bank (since acquired by Bank of America), where she was responsible for relationship management and marketing of co-branded financial products.

In addition to developing strategic media relations opportunities for her clients in key financial, healthcare, metals and mining and other key industry trade publications, she provides brand branding and marketing consultation, including logo and website design and marketing collateral development.

Cathy started her career as a Copywriter with Jones/Kent & Associates, an advertising and marketing communications firm. Cathy is a graduate of the University of Delaware, where she earned a B.A. in English with Business and Technical Writing concentration. She is based in New York City.

Melanie Senior, MSc (Cantab), MA

Melanie is a writer and analyst with nearly 20 years’ experience covering the life sciences industry. She writes regularly for Nature Biotechnology, IN VIVO and Medtech Strategist about science and technology, finance, strategy and market access. She has published numerous in-depth reports on key issues facing the industry, from real-world evidence to digital technology, AI and pricing pressure.

Melanie also works with companies, investors and associations to help formulate and communicate their strategies and strengths. Past and present clients include the BioIndustry Association, the Alliance for Regenerative Medicine, Bioscience Managers, MedCity, ThermoFisher, Cytel, Shire Pharmaceuticals and Informa Business Intelligence.

Outside of the UK, Melanie has worked with the Life Sciences team at EY and with French, German and Norwegian biotech and med-tech start-ups. She has also worked with US-based companies including market-access focused Real Endpoints.

Melanie has held various editorial positions within Elsevier, Windhover Information and at the Financial Times Group, where she began her career after gaining a first-class degree in Natural Sciences from Cambridge University.

Melanie continues to develop her understanding of health economics and science through post-graduate qualifications in International Health Technology Assessment (University of Sheffield) and Sports Nutrition (St. Mary’s University, Twickenham). She speaks fluent French and good German.

Fiona Brown BA, MCIPR, MCIM

Fiona is a corporate communications specialist with 30 years experience in life sciences. She ran her own agency in the 1980s

working for the pharmaceutical, dental and animal health divisions of ICI and subsequently acted for 10 years as PR consultant to the Rothschild fund, Biotechnology Investments Limited.

Fiona has provided commercial and investor relations consultancy to a broad spectrum of companies including Shire Pharmaceuticals, IGEN Europe, Atugen AG, McCormick UK , Physiomics plc, Biovector Therapeutics SA, Healthcare Ventures Limited, 1st European Conference on Bone Morphogenic Proteins, Investing in Biotechnology Conference, London Regenerative Medicine Network and

Fiona has a BA in English, History and Philosophy from London University, and further training in marketing (CAM) and molecular biology (Birkbeck). A particular strength lies in interpreting science for a lay audience and translating this into informative copy across the various platforms available to today’s marketer.